Inclusion Criteria:

- Histologically confirmed ovarian epithelial or primary peritoneal carcinoma

- Recurrent or persistent after initial standard surgery or chemotherapy

- Incurable with standard surgery, chemotherapy, or radiotherapy

- At least 1 unidimensionally measurable target lesion

- At least 20 mm by conventional techniques

- At least 10 mm by spiral CT scan

- Outside the area of prior radiotherapy

- Accessible to guided core needle biopsy

- Received 1 prior platinum-based chemotherapy regimen (e.g., carboplatin, cisplatin,
or another organoplatinum compound) for primary disease

- May have included high-dose therapy, consolidation, or extended therapy
administered after surgical or non-surgical assessment

- Patients with only 1 prior platinum-based chemotherapy regimen must have an
initial treatment-free interval of less than 12 months

- Patients with an initial treatment-free interval of more than 12 months must
have progressive disease after prior platinum-based chemotherapy regimen as
second-line therapy

- No tumors involving major blood vessels

- No evidence of CNS disease (primary brain tumor or brain metastases) within the past
5 years

- Ineligible for higher priority GOG protocols (i.e., active phase III GOG protocols
for the same patient population)

- Performance status - GOG 0-2 (patients who have received 1 prior regimen)

- Performance status - GOG 0-1 (patients who have received 2 prior regimens)

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- No known bleeding disorder or coagulopathy

- No active bleeding

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- SGOT ≤ 2.5 times ULN

- Alkaline phosphatase ≤ 2.5 times ULN

- PT (INR) ≤ 1.5 (INR 2-3 if on stable dose of therapeutic warfarin or low molecular
weight heparin)

- PTT < 1.2 times control

- Creatinine ≤ 1.5 times ULN

- Creatinine clearance > 60 mL/min

- No proteinuria, as indicated by 1 of the following:

- Negative urine dipstick

- Urine protein < 30 mg/dL

- Urine protein < 1,000 mg on 24-hour urine collection

- No clinically significant cardiovascular disease, including any of the following:

- Uncontrolled hypertension

- Myocardial infarction within the past 6 months

- Unstable angina within the past 6 months

- New York Heart Association class II-IV congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Peripheral vascular disease ≥ grade 2

- No stroke within the past 5 years

- No pathologic condition that carries a high risk of bleeding

- No significant traumatic injury within the past 28 days

- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

- No uncontrolled seizures within the past 5 years

- No neuropathy (motor and sensory) ≥ grade 2

- No serious non-healing wound, ulcer, or bone fracture

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human or humanized antibodies

- No active infection requiring parenteral antibiotics

- No known claustrophobia that would preclude MRI tolerance

- No ferromagnetic implants or pacers

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 3 months
after study treatment

- At least 3 weeks since prior immunologic therapy directed at malignancy

- No prior bevacizumab

- No other concurrent immunotherapy directed at malignancy

- One additional prior cytotoxic regimen for recurrent or persistent disease allowed

- No prior non-cytotoxic chemotherapy for recurrent or persistent disease

- No concurrent chemotherapy directed at malignancy

- At least 1 week since prior hormonal therapy directed at malignancy

- No concurrent hormonal therapy directed at malignancy

- Concurrent hormone replacement therapy allowed

- Recovered from prior radiotherapy

- No concurrent radiotherapy directed at malignancy

- At least 28 days since prior major surgery or open biopsy and recovered

- At least 7 days since prior core biopsy or placement of vascular access device

- No anticipated need for major surgical procedure during study participation

- At least 3 weeks since other prior therapy directed at malignancy

- No prior anticancer therapy that would preclude study entry